Effect of cis-diammine dichloroplatinum on vascular endothelial growth factor expression in uterine cervical carcinoma

Purpose of investigation: In this study, we investigated the effects of cis-diammine dichloroplatinum (CDDP) on VEGF mRNA expression and VEGF production in uterine cervical carcinoma tissues obtained from patients with locally advanced disease and in CaSki cells cultured in vitro.

Methods: VEGF in cultured CaSki cells and in the culture media was measured using a sensitive enzyme-linked immunosorbent assay (ELISA) before and 24 h, 48 h and 72 h after 3 h exposure to CDDP. VEGF mRNA expression in CaSki cells was assessed by the semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) before and 24 h and 48 h after 3 h exposure to CDDP. We also examined the effect of CDDP on microvessel counts in uterine cervical carcinoma tissues obtained before and after high-dose CDDP intraarterial chemotherapy. Immunohistochemical staining using a monoclonal antibody against CD34 was carried out with cervical carcinoma tissue specimens, and microvessel counts were quantified by counting vessels.

Results: CDDP treatment resulted in significant increases in not only VEGF concentrations in cultured CaSki cells and culture media but also in VEGF mRNA expression levels in cultured CaSki cells in a time-dependent and dose-dependent manner compared to untreated controls (p < 0.05, n = 5). On the other hand, VEGF concentrations and microvessel counts in cervical carcinoma tissues were significantly lower in cases with complete response (CR) and partial response (PR), compared to those before treatment (p < 0.05, n = 5 ). By contrast, in cases with no change (NC) to CDDP, both VEGF concentrations and microvessel counts did not decrease and rather showed a somewhat increase compared with levels prior to the treatment.

Conclusions: These results suggest that CDDP-induced increases in VEGF production by cervical carcinoma cells may stimulate angiogenesis in the tumor lesion after CDDP treatment.

VEGF; Uterine cervical carcinoma; CaSki cells; RT-PCR; CDDP; Percutaneous pelvic perfusion extracorporeal chemofiltration (PPPEC).

[1] Folkman J.:'The role of angiogenesis in tumor growth". Semin Cancer Biol., 1992, 3, 65.

[2] Folkman J.: "What is the evidence that tumors are angiogenesis dependent'?". J. Natl. Cancer Inst., 1990, 82, 4.

[3] Weidner N..S emple J.P.,W elch W.R., Folkman J.:'Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma". N. Engl. J. Med., 1991, 324, 1.

[4] LiottaL.,K leinerman J.,S aidel G.M.: "Quantitative relationships of intra vascular tumors cells, tumor vessels, and plumonary metastases following tumor implication". Cancer Res., 1974. 34, 997.

[5] Kaku T., Kamura T., Kinukawa N., Kawauchi S., Tsuneyoshi M., Nakano H. et al.: "Angiogenesis in endometrial carcinoma". Cancer, 1997, 80, 741.

[6] Mattern J., Stammler G., Koomagi R., Wallwiener D., Kaufmann M., Volm M.: "Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma". Anticancer Res., 1997, 17, 621.

[7] Dirix L.Y., Vermeulen P.B., Pawinski A., Martin M.. Van Oosterom A.T.: "Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients". Br. J. Cancer, 1997. 76, 238.

[8] Stafl A., Mattingly R.F.:'"Angiogenesis of cervical neoplasia'' Am. J. Ohstet. Gynecol., 1975. 121, 845.

[9] Chomette G.. Auriol M., Tranbaloc P.. Blondon J.: "Intraepithelial neoplasm of the uterine cervix and angiogenesis; morphologic study". Arch. Anal. Cytol. Pathol., 1989, 37, 73.

[10] Smith-McCune K.K.,W eidner N.: "Demonstration and characterization of the angiogenic properties of cervical dysplasia". Cancer Res., 1994. 54, 800.

[11] Sillman F., Boyce J., Fruchter R.: "The significance of atypical vessels and neovascularization in cervical neoplasia". Am. J Ohstet. Gyne(.ol., 1981, 139, 154.

[12] Loncaster J.A.. Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., West CM.: "Vasrnlar endothelial growth factor (YEGF) expression is a prognostic fac'tor for radiotherapy outcome in advanced carcinoma or the cervix". B1: J. Cancer, 2000,8 3, 620.

[13] Shishido T.,Y asoshima T.,D enno T.,M ukaiya M.,S ato N., Hirata K.: "lnhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin". Jpn. J. Cancer Res., 1998, 89, 963.

[14] Emoto M.. Ishiguro M., Iwasaki H., Kikuchi M., Kawarabayashi T.:'TNP-470 inhibits growth and production of vascular endothelial growth factor of uterine carcinosarcoma cells". Anticancer Res., 2000, 20, 601.

[15] Santin A.D., Hermonat P.L., Ravaggi A., Pecorelli S., Cannon M.J.. Parham G.P.: "Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix". Ohstet. Gynecol., 1999. 94, 78.

[16] Dinh T.V., Hannigan E.V.. Smith E.R., Hove M.J., Chopra V.. ToT.: "Tumor angiogenesis as a predictor of recurrence in stage lb squamous cell carcinoma of the cervix". Obstet. Gynecol., 1996, 87, 751.

[17] Hamama S., Motoyama S., Yoshida S., Miyahara Y., Tateiwa Y., Maruo T.: "Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perti.lsion with extracorporeal chemofiltration for advanced uterine cervical carcinoma. l. Analysis for ph,mnacokinetics, tumor response, and toxicity of platinum". Am. J. Clin. Oneal., 2001, 24, 241.

[18] Motoyama S., Hamana S., Miyahara Y., Tateiwa Y., Yoshida S., Maruo T.: "Super high-dose intraarterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma. II. Its impact on clinical response and sub、e4uent surgery". Am. J. Clin. Oncol., 2001, 24, 247.

[19] Ishikawa H., Kikkawa F.. Tamakoshi K., Matsuzawa K., Suganuma N., Tomoda Y. et al.: "Distribution of platinum in human gynecologic tissue and lymph nodes after intravenous and intraarterial neoadjvant chemotherapy". Anticancer Res., 1996, 16, 3849.

[20] Bradford M.: "A rapid and sen、itive method for the quantitaion of microgram quantities of protein utilizing the principle of proteindye binding". Anal. Biochem., 1976, 72, 248.

[21] Maruo T., Mochizuki M.: "lmmunohistochemical localization of epidermal growth f<lctor receptor and myc oncogene product in human placenta: implication for trophblast proliferation and differentiation". Am. J. Ohstet. Gynecol., 1987, 156, 721.

[22] Guidi A.J.,Abu-Jawdeh G., Berse B., Tognazzi K.. Dvorak H.F., Brown L.F. et al.: "Vascular permeab山ty factor (Vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia". J. Natl. Cancer Inst., 1995, 87, 1237.

[23] Obermair A.,W anner C.,B ilgi S.,S peiser P.,L eodolter S.. Gitsch G. et al.:'Tumor angiogenesis in stage lh cervical cancer: Correlation of microvessel density with survival". Am. J. Ohstet Gynecol., 1998, 178, 314.

[24] Dellas A., Moch H., Schultheiss E., Feichter G., Gudat F.,Torhorst J.: "Angiogenesis in cervical neoplasia: Microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations". Gynecol. Oneal., 1997, 67, 27.

[25] Lissoni P., Fugamalli E., Malugani F., Ardizzoia A., Tancini G., Gardani G.S. et al.: "Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer". Int. J. Biol. Markers, 2000, 15, 308.

[26] Kohno Y., lwanari O., Kitao M.: "Prognostic importance of histologic vascular density in cervical cancer treated with hypertensitive intraarterial chemotherapy". Cancer, 1993, 72, 2394.

[27] Katoh O., Takahashi T., Oguri T., Kobayashi M., Hirata S., Watanabe H.: "Vasucular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCLl acting as an antiapoptotic factor". Cancer Res., 1998, 58, 5565.

[28] Fernandez A., Udagawa T., Schwesinger C., Beecken W., McDonnell T., D'Amato R.: "Angiogenetic potential of prostate carcinoma cells overexpressing bcl-2". J. Natl. Cancer Inst., 2001, 93, 208.

[29] Foekens J.A., Peters H.A., Geurts-Moespot A., Sweep C.G., Klijn J.G.: "High tumor levels of vascular endothelial factor predict poor response to systemic therapy in advanced breast cancer". Cancer Res., 2001, 61, 5407.

[30] Yanase T., Tamura M., Fujita K., Kodama S., Tanaka K.: "Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell line in vitro and in vivo". Cancer Res., 1993, 53, 2566.

[31] Kusaka M., Sudo K., Matsutani E., Ingber D., Folkman J.: "Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470". Br. J. Cancer, 1994, 69, 212.

[32] Yamamoto T., Sudo K., Fujita T.: " Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470". Anticancer Res., 1994, 14, 1.

[33] Shishido T., Yasoshima T., Denno R.: "Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inh加tor, TNP-470". Cancer Res., 1996, 87, 958.

[34] Kato T., Sato K., Kakinuma H., Matsuda Y.: "Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice". Cancer Res., 1994, 54, 5143.

[35] Yamaoka M., Yamamoto T., Ikeyama S., Sudo K., Fujita T.: "Angiogenesis inhibitor TNP-470 potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell line". Cancer Res., 1993, 53, 5233.